A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 Apr 2017 Planned End Date changed from 1 Sep 2018 to 31 Dec 2020.
- 07 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2017.
- 07 Sep 2016 Status changed from recruiting to active, no longer recruiting.